scholarly journals The effect of a human pancreatic α‐amylase inhibitor, montbretin A, on the chronic treatment of type 2 diabetes

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Violet G. Yuen ◽  
Gary Brayer ◽  
Stephen Withers ◽  
Raymond Andersen ◽  
John Coleman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Treatment ◽  
Amylase Inhibitor

Structure-based design of human pancreatic amylase inhibitors from the natural anthocyanin database for type 2 diabetes

2020 ◽  
Vol 11 (4) ◽  
pp. 2910-2923 ◽  
Author(s):  
Lianghua Xie ◽  
Jianling Mo ◽  
Jingdan Ni ◽  
Yang Xu ◽  
Hongming Su ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Design Approach ◽  
Pancreatic Amylase ◽  
Amylase Inhibitor ◽  
Amylase Inhibitors

Malvidin 3-O-arabinoside is identified as a novel human pancreatic amylase inhibitor from the natural anthocyanin database with a structure-based design approach.

Increase in cortisol/ACTH ratio after chronic treatment with liraglutide in patients with type 2 diabetes

2017 ◽  
Vol 43 (4) ◽  
pp. 398-399 ◽  
Author(s):  
S. Kamei ◽  
H. Kaneto ◽  
A. Tanabe ◽  
T. Kinoshita ◽  
A. Obata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Treatment

scholarly journals Potential compounds phenolic group sawo leaves (Manilkara zapota) as an α-amylase inhibitor in type 2 diabetes mellitus by in silico

2021 ◽  
Author(s):  
Siti Imroatul Maslikah ◽  
Rif'atul Chusnul Khuluq ◽  
Ilfia Kholifaturrohmah ◽  
Lintang Miftahul Rizki ◽  
Atikah Amalia
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
In Silico ◽  
Manilkara Zapota ◽  
Amylase Inhibitor ◽  
Phenolic Group

scholarly journals Thermotherapy Effects on Healthy and Type 2 Diabetes Human Skeletal Muscle Myoblast Cell Lines

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Janette A. Lindstrom ◽  
Felix Omoruyi ◽  
Jean Sparks
Keyword(s):  
Oxidative Stress ◽  
Type 2 Diabetes ◽  
Skeletal Muscle ◽  
Cell Lines ◽  
Acute Treatment ◽  
Human Skeletal Muscle ◽  
Chronic Treatment ◽  
Muscle Cells ◽  
Skeletal Muscle Cells

Diabetes mellitus is a chronic metabolic disease characterized by elevated blood glucose levels with associated disordered carbohydrate and lipid metabolism. Type 2 diabetes (T2D) specifically has been shown to cause a decrease in skeletal muscle mass due to oxidative stress. This study investigated a treatment option for T2D through thermotherapy on healthy (HSMM) and T2D (D-HSMM) human skeletal muscle cells. The goals were to determine the effects of thermotherapy, long-term (chronic) and short-term (acute), on HSMM and D-HSMM cell viabilities and oxidative stress. HSMM and D-HSMM cells were grown to confluency, harvested, and counted to determine density. Acute and chronic heat treatments were applied to both cell lines. The chronic treatment consisted of a 30-minute exposure to 40°C, three times a week for three weeks; the acute treatment was a one-time exposure. Oxidative stress assays and cell viabilities were tested 24 hours after heat treatments. Results indicated no significant effect on the cell viability of HSMM and D-HSMM cells. The acute treatment had a significant increase ( p ≤ 0.05 ) of MDA concentration compared to the chronic treatment. The chronic treatment had a significant increase ( p ≤ 0.05 ) in catalase activity compared to the acute treatment. The SOD activity had no significant change ( p > 0.05 ) between the chronic and acute treatments. In conclusion, acute thermotherapy may not be beneficial for skeletal muscle cells due to the observed increase in oxidative stress, especially in the D-HSMM cells.

scholarly journals Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial

2016 ◽  
Vol 174 (4) ◽  
pp. 513-522 ◽  
Author(s):  
Daniele Santi ◽  
Antonio R M Granata ◽  
Alessandro Guidi ◽  
Elisa Pignatti ◽  
Tommaso Trenti ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Erectile Dysfunction ◽  
Erectile Function ◽  
Chronic Treatment ◽  
Double Blind ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Testosterone Levels ◽  
Male Patients

ObjectiveType 2 diabetes mellitus (T2DM) is associated with endothelial dysfunction, characterized by a reduction of nitric oxide (NO)-mediated relaxation. Phosphodiesterase type 5 inhibitors (PDE5i) improve NO levels. The aim of the study was to investigate whether long-term, chronic treatment with the PDE5i vardenafil improves systemic endothelial function in diabetic men.DesignA prospective, investigator-initiated, randomized, placebo-controlled, double-blind, clinical trial was conducted.MethodsIn total, 54 male patients affected by T2DM, diagnosed within the last 5 years, and erectile dysfunction were enrolled, regardless of testosterone levels. In all, 26 and 28 patients were assigned to verum and placebo groups respectively. The study consisted of an enrollment phase, a treatment phase (24 weeks) (vardenafil/placebo 10 mg twice in a day) and a follow-up phase (24 weeks). Parameters evaluated were as follows: International Index of Erectile Function 15 (IIEF-15), flow-mediated dilation (FMD), serum interleukin 6 (IL6), endothelin 1 (ET-1), gonadotropins and testosterone (measured by liquid chromatography/tandem mass spectrometry).ResultsIIEF-15 erectile function improved during the treatment (P<0.001). At the end of the treatment both FMD (P=0.040) and IL6 (P=0.019) significantly improved. FMD correlated with serum testosterone levels (R2=0.299;P<0.001). Testosterone increased significantly under vardenafil treatment and returned in the eugonadal range only in hypogonadal men (n=13), without changes in gonadotropins. Chronic vardenafil treatment did not result in relevant side effects.ConclusionThis is the first double-blind, placebo-controlled clinical trial designed to evaluate the effects of chronic treatment of vardenafil on endothelial health-related parameters and sexual hormones in patients affected by a chronic disease. Chronically administered vardenafil is effective and improves endothelial parameters in T2DM patient. Moreover, chronic vardenafil therapy improves hypogonadism in diabetic, hypogonadal men.

scholarly journals Magnificamide is a new effective mammalian a-amylase inhibitor

2019 ◽  
Vol 489 (4) ◽  
pp. 429-432
Author(s):  
O. V. Sintsova ◽  
E. V. Leychenko ◽  
I. N. Gladkikh ◽  
A. P. Kalinovskii ◽  
M. M. Monastyrnaya ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Kinetic Parameters ◽  
Metabolic Disorders ◽  
Amylase Inhibitor ◽  
Prevention And Treatment ◽  
Heteractis Magnifica ◽  
Medical Drug

Recombinant analog of sea anemone Heteractis magnifica peptide was obtained and kinetic parameters of its interaction with mammalian -amylases were determined. Magnificamide inhibits -amylases significantly stronger than a medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.

Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes

2020 ◽  
Vol 133 (2) ◽  
pp. 430-438 ◽  
Author(s):  
Jean-Charles Preiser ◽  
Bruna Provenzano ◽  
Wasineeart Mongkolpun ◽  
Katarina Halenarova ◽  
Miriam Cnop
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Treatment ◽  
Perioperative Management ◽  
Oral Glucose ◽  
Glucose Lowering ◽  
Patients With Diabetes ◽  
The Right

The right management of oral glucose-lowering drugs aims to identify, assess, and follow patients with diabetes and avoid unnecessary interruptions of the chronic treatment.

Sign in / Sign up

Export Citation Format

Share Document